ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.

J Neurol Neurosurg Psychiatry · 2016 · PMC5013117 · PMID 27010616

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Among all the assessments, ADCOMS provided the strongest evidence (p<0.0001) for treatment differences, with the benefit assessed using ADAS-cog (p=0.0008), MMSE (p=0.00095) and CDR-SB (p=0.017) not being as highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.